Inovio Pharmaceuticals, Inc.
MERS-CoV vaccine
Last updated:
Abstract:
Disclosed herein is a vaccine comprising a Middle East Respiratory Syndrome coronavirus (MERS-CoV) antigen. The antigen can be a consensus antigen. The consensus antigen can be a consensus spike antigen. Also disclosed herein is a method of treating a subject in need thereof, by administering the vaccine to the subject.
Status:
Grant
Type:
Utility
Filling date:
4 Feb 2020
Issue date:
5 Oct 2021